Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/μL

Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/μL

Objectives: To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/μL. Material and Method: A retrospective cohort study was conducted among antiretroviral-naive HIV-infected patients...

Saved in:

書目詳細資料
Main Authors:	Weerawat Manosuthi, Somnuek Sungkanuparph, Somsit Tansuphaswadikul, Suthat Chottanapund, Wiroj Mankatitham, Sukanya Chimsuntorn, Chayanan Sittibusaya, Visal Moolasart, Achara Chaovavanich
其他作者:	Thailand Ministry of Public Health
格式:	Article
出版:	2018
主題:	Medicine
在線閱讀:	https://repository.li.mahidol.ac.th/handle/123456789/19768
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/μL
由: Weerawat Manosuthi, et al.
出版: (2018)

Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting
由: Weerawat Manosuthi, et al.
出版: (2018)

Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients
由: Weerawat Manosuthi, et al.
出版: (2018)

Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone
由: Sukanya Chimsuntorn, et al.
出版: (2018)

Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study
由: Weerawat Manosuthi, et al.
出版: (2018)

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3
由: Weerawat Manosuthi, et al.
出版: (2018)

Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: A case-control study
由: Weerawat Manosuthi, et al.
出版: (2018)

Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis
由: Weerawat Manosuthi, et al.
出版: (2018)

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin
由: Weerawat Manosuthi, et al.
出版: (2018)

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin
由: W. Manosuthi, et al.
出版: (2018)

Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: A four-year prospective study
由: Weerawat Manosuthi, et al.
出版: (2018)

Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole
由: Weerawat Manosuthi, et al.
出版: (2018)

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis
由: Weerawat Manosuthi, et al.
出版: (2018)

Mortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitis
由: Weerawat Manosuthi, et al.
出版: (2018)

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study
由: Weerawat Manosuthi, et al.
出版: (2018)

Letter to the editor: Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting [1]
由: Somnuek Sungkanuparph, et al.
出版: (2018)

Survival rate and risk factors of mortality among HIV/tuberculosis- coinfected patients with and without antiretroviral therapy
由: Weerawat Manosuthi, et al.
出版: (2018)

CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy
由: Weerawat Manosuthi, et al.
出版: (2018)

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients
由: Weerawat Manosuthi, et al.
出版: (2018)

Single-boosted protease inhibitor versus double-boosted protease inhibitors for the salvage therapy in HIV-infected patients
由: Weerawat Manosuthi, et al.
出版: (2018)

Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: A 144-week prospective study
由: Weerawat Manosuthi, et al.
出版: (2018)

Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash
由: Weerawat Manosuthi, et al.
出版: (2018)

Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting
由: Weerawat Manosuthi, et al.
出版: (2018)

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails
由: Somnuek Sungkanuparph, et al.
出版: (2018)

Nevirapine- versus efavirenz-based highly acitve antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection
由: W. Manosuthi, et al.
出版: (2018)

Reply to chang et al
由: Weerawat Manosuthi, et al.
出版: (2018)

Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy
由: Somnuek Sungkanuparph, et al.
出版: (2018)

Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count
由: Somsit Tansuphaswadikul, et al.
出版: (2018)

Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting
由: Weerawat Manosuthi, et al.
出版: (2018)

Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cells counts in resource-limited settings
由: Sasisopin Kiertiburanakul, et al.
出版: (2018)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
由: Weerawat Manosuthi, et al.
出版: (2018)

HIV-1 drug resistance-associated mutations among antiretroviral-naive thai patients with chronic HIV-1 infection
由: Weerawat Manosuthi, et al.
出版: (2018)

Comparison of thai government manufactured tenofovir (Tenofovir GPO300) with privately manufactured tenofovir (Viread) used along with lamivudine and efavirenz to treat Thai HIV patients
由: Weerawat Manosuthi, et al.
出版: (2018)

Long-term seroprotective response of trivalent seasonal influenza vaccine in HIV-infected children, regardless of immunogenicity before immunisation
由: Visal Moolasart, et al.
出版: (2018)

HLA-B* 3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients
由: Soranun Chantarangsu, et al.
出版: (2018)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
由: Weerawat Manosuthi, et al.
出版: (2018)

Nevirapine induced mitochondrial dysfunction in HepG2 cells
由: Paemanee A., et al.
出版: (2017)

Nevirapine induced mitochondrial dysfunction in HepG2 cells
由: Atchara Paemanee, et al.
出版: (2018)

Nevirapine induces apoptosis in liver (HepG2) cells
由: Jeerang Wongtrakul, et al.
出版: (2018)

Nevirapine induced mitochondrial dysfunction in HepG2 cells
由: Atchara Paemanee, et al.
出版: (2018)